The IMPact of untReated nOn-Valvular atrial fibrillation on short-tErm clinical and economic outcomes in the US Medicare population: the IMPROVE-AF model

References

• January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):e199–e267.
   PubMed Web of Science ®Google Scholar
• Colilla S, Crow A, Petkun W, et al. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. Adult population. Am J Cardiol. 2013;112(8):1142–1147.
   PubMed Web of Science ®Google Scholar
• Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: the AnTicoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA. 2001;285(18):2370.
   PubMed Web of Science ®Google Scholar
• Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the framingham study. Stroke. 1991;22(8):983–988.
   PubMed Web of Science ®Google Scholar
• Freeman JV, Zhu RP, Owens DK, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med. 2011;154(1):1–11.
   PubMed Web of Science ®Google Scholar
• Joo H, Dunet DO, Fang J, et al. Cost of informal caregiving associated with stroke among the elderly in the United States. Neurology. 2014;83(20):1831–1837.
   PubMed Web of Science ®Google Scholar
• Go AS, Hylek EM, Chang Y, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA. 2003;290(20):2685–2692.
   PubMed Web of Science ®Google Scholar
• January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the american college of cardiology/american heart association task force on clinical practice guidelines and the heart rhythm society in collaboration with the society of thoracic surgeons. Circulation. 2019;140(2):e125–e151.
   PubMed Web of Science ®Google Scholar
• Stangier J, Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost. 2009;15(1_suppl):9S–16S.
   PubMed Web of Science ®Google Scholar
• Food & Drug Administration. Pradaxa highlights of prescribing information. Published online October 2010; [cited 2020 July 16]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022512s000lbl.pdf.
   Google Scholar
• Food & Drug Administration. Xarelto highlights of prescribing information. Published online November 2012; [cited 2020 July 16]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022406s001s002s003lbl.pdf.
   Google Scholar
• Food & Drug Administration. Eliquis highlights of prescribing information. Published online December 2012; [cited 2020 July 16]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202155s000lbl.pdf.
   Google Scholar
• Food & Drug Administration. Savaysa highlights of prescribing information. Published online January 2015; [cited 2020 July 18]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf.
   Google Scholar
• Casciano JP, Dotiwala ZJ, Martin BC, et al. The costs of warfarin underuse and nonadherence in patients with atrial fibrillation: a commercial insurer perspective. J Manag Care Pharm. 2013;19(4):302–316.
   PubMed Web of Science ®Google Scholar
• Mazurek M, Huisman MV, Rothman KJ, et al. Regional differences in antithrombotic treatment for atrial fibrillation: insights from the GLORIA-AF phase II registry. Thromb Haemost. 2017;117(12):2376–2388.
   PubMed Web of Science ®Google Scholar
• Di Fusco M, Sussman M, Barnes G, et al. The burden of nontreatment or undertreatment among non-valvular atrial fibrillation patients with elevated stroke risk: a systematic literature review of real-world evidence. Circulation. 2020;142(Suppl_3):A15651.
   Google Scholar
• Munir B, Hlavacek P, Keshishian A, et al. Underutilization of oral anticoagulant therapy among elderly patients with atrial fibrillation: insights from the United States medicare database. J Am Coll Cardiol. 2021;77(18):1641.
   PubMed Web of Science ®Google Scholar
• Patel AA, Ogden K, Veerman M, et al. The economic burden to medicare of stroke events in atrial fibrillation populations with and without thromboprophylaxis. Popul Health Manag. 2014;17(3):159–165.
   PubMed Web of Science ®Google Scholar
• Centers for Medicare & Medicaid Services. 2018 medicare enrollment section of CMS program statistics. Published online February 13, 2020; [cited 2021 April 7]. Available from: cms.gov/research-statistics-data-systems/cms-program-statistics/2018-medicare-enrollment-section.
   Google Scholar
• Turakhia MP, Shafrin J, Bognar K, et al. Estimated prevalence of undiagnosed atrial fibrillation in the United States. PLoS One. 2018;13(4):e0195088.
   PubMed Web of Science ®Google Scholar
• Marzec LN, Wang J, Shah ND, et al. Influence of direct oral anticoagulants on rates of oral anticoagulation for atrial fibrillation. J Am Coll Cardiol. 2017;69(20):2475–2484.
   PubMed Web of Science ®Google Scholar
• Hsu JC, Maddox TM, Kennedy KF, et al. Oral anticoagulant therapy prescription in patients with atrial fibrillation across the spectrum of stroke risk: insights from the NCDR PINNACLE Registry. JAMA Cardiol. 2016;1(1):55–62.
   PubMed Web of Science ®Google Scholar
• Friberg L, Rosenqvist M, Lip GYH. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182,678 patients with atrial fibrillation: the Swedish atrial fibrillation cohort study. Eur Heart J. 2012;33(12):1500–1510.
   PubMed Web of Science ®Google Scholar
• Lip GYH, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk Factor-Based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263–272.
   PubMed Web of Science ®Google Scholar
• Singer DE, Chang Y, Borowsky LH, et al. A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score. JAHA. 2013;2(3):250.
   Web of Science ®Google Scholar
• Patti G, Lucerna M, Pecen L, et al. Thromboembolic risk, bleeding outcomes and effect of different antithrombotic strategies in very elderly patients with atrial fibrillation: a sub-analysis from the PREFER in AF (PREvention of thromboembolic Events-European registry in atrial fibrillation). J Am Heart Assoc. 2017;6(7):5657.
   PubMed Web of Science ®Google Scholar
• Lip GYH, Keshishian A, Li X, et al. Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients: the ARISTOPHANES study. Stroke. 2018;49(12):2933–2944.
   PubMed Web of Science ®Google Scholar
• Fang MC, Go AS, Hylek EM, et al. Age and the risk of Warfarin-Associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation study: age and warfarin-associated hemorrhage risk. J Am Geriatr Soc. 2006;54(8):1231–1236.
   PubMed Web of Science ®Google Scholar
• Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. The Lancet. 2014;383(9921):955–962.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806–817.
   PubMed Web of Science ®Google Scholar
• Sussman M, Menzin J, Lin I, et al. Impact of atrial fibrillation on stroke‐related healthcare costs. J Am Heart Assoc. 2013;2(6):479.
   Web of Science ®Google Scholar
• US Bureau of Labor Statistics. Consumer price index for all urban consumers: medical care in U.S. City Average. Published online August 2020; [cited 2020 Aug 21]. Available from https://data.bls.gov/timeseries/CUUR0000SAM.
   Google Scholar
• Centers for Medicare & Medicaid Services. Medicare part D drug spending dashboard & data. Published online December 22, 2020; [cited 2021 Aug 7]. Available from: https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Information-on-Prescription-Drugs/MedicarePartD.
   Google Scholar
• Wang C-Y, Pham PN, Thai TN, et al. Updating the cost effectiveness of oral anticoagulants for patients with atrial fibrillation based on varying stroke and bleed risk profiles. Pharmacoeconomics. 2020;38(12):1333–1343.
   PubMed Web of Science ®Google Scholar
• Leibson CL, Hu T, Brown RD, et al. Utilization of acute care services in the year before and after first stroke: a population-based study. Neurology. 1996;46(3):861–869.
   PubMed Web of Science ®Google Scholar
• Holloway RG, Witter DM, Lawton KB, et al. Inpatient costs of specific cerebrovascular events at five academic medical centers. Neurology. 1996;46(3):854–860.
   PubMed Web of Science ®Google Scholar
• US Bureau of Labor Statistics. Average hours per day spent in selected activities by age. Published online June 25, 2020; [cited 2021 Aug 6]. Available from: https://www.bls.gov/charts/american-time-use/activity-by-age.htm.
   Google Scholar
• US Bureau of Labor Statistics. Average hourly and weekly earnings of all employees on private nonfarm payrolls by industry sector, seasonally adjusted; [cited 2021 Aug 18]. Available from: https://www.bls.gov/news.release/empsit.t19.htm.
   Google Scholar
• Charlton B, Adeboyeje G, Barron JJ, et al. Length of hospitalization and mortality for bleeding during treatment with warfarin, dabigatran, or rivaroxaban. PLoS One. 2018;13(3):e0193912.
   PubMed Web of Science ®Google Scholar
• Fanikos J, Grasso-Correnti N, Shah R, et al. Major bleeding complications in a specialized anticoagulation service. Am J Cardiol. 2005;96(4):595–598.
   PubMed Web of Science ®Google Scholar
• Thygesen SK, Frost L, Eagle KA, et al. Atrial fibrillation in patients with ischemic stroke: a population-based study. Clin Epidemiol. 2009; 1:55–65.
   PubMedGoogle Scholar
• Burn J, Dennis M, Bamford J, et al. Long-term risk of recurrent stroke after a first-ever stroke. The oxfordshire community stroke project. Stroke. 1994;25(2):333–337.
   PubMed Web of Science ®Google Scholar
• Kolominsky-Rabas PL, Weber M, Gefeller O, et al. Epidemiology of ischemic stroke subtypes according to TOAST criteria: incidence, recurrence, and long-term survival in ischemic stroke subtypes: a population-based study. Stroke. 2001;32(12):2735–2740.
   PubMed Web of Science ®Google Scholar
• Mohan KM, Crichton SL, Grieve AP, et al. Frequency and predictors for the risk of stroke recurrence up to 10 years after stroke: the South london stroke register. J Neurol Neurosurg Psychiatry. 2009;80(9):1012–1018.
   PubMed Web of Science ®Google Scholar
• Mohan KM, Wolfe CDA, Rudd AG, et al. Risk and cumulative risk of stroke recurrence: a systematic review and meta-analysis. Stroke. 2011;42(5):1489–1494.
   PubMed Web of Science ®Google Scholar